Please select the eligibility criteria that correspond to the clinical trial below.
Title: Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial
Brief Summary: To assess if a sequential treatment regimen better eradicates H. pylori than does a triple drug regimen in adults with dyspepsia or peptic ulcer disease.


Options:
A: Inclusion Criteria:

* Consecutive H. pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis

Exclusion Criteria:

* previous H. pylori-eradication therapy
* ingestion of antibiotics, bismuth, or proton pump inhibitors within the prior 4 weeks
* patients with allergic history to the medications used
* patients with previous gastric surgery
* the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
* pregnant women
B: Inclusion Criteria:

* consecutive patients newly diagnosed to have H. pylori infection.

Exclusion Criteria:

* known allergy to any of the treatment drugs
* inability to undergo routine test to confirm success of H. pylori eradication
* previous H. pylori therapy.
C: Inclusion Criteria:

* Helicobacter pylori infected patients \> 18 years

Exclusion Criteria:

* previous H. pylori eradication treatment;
* Use of proton pump inhibitors, H2-receptor antagonists, bismuth preparations and antibiotics in the previous 4 weeks;
* Concomitant anticoagulant or ketoconazole use, due to the potential of interaction with the study medications;
* Zollinger-Ellison syndrome;
* Previous surgery of the esophagus and/or upper gastrointestinal tract (with the exception of appendectomy, polypectomy and cholecystectomy);
* Severe or unstable cardiovascular, pulmonary, or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematological disorder; any other clinically significant medical condition that could increase the risk to the study participants; malignant disease of any kind during the previous 5 years except for successfully treated skin (basal or squamous cell) cancer or Barrett esophagus with high grade dysplasia;
* Drug or medication abuse within the past year;
* Severe psychiatric or neurological disorders;
* Pregnant or nursing women sexually active women of child bearing potential who were not willing to practice medically acceptable contraception (oral contraceptives; inject able/implantable or mechanical devices as well as vasectomy of the sexual partner) for the entire duration of the study.
D: Inclusion Criteria:

* positive Urea Breath Test documenting H. pylori infection
* age 21 - 65 years
* no known allergies to study drugs
* only member of household participating in study
* no known medical conditions (other than H. pylori) that would preclude or require antibiotic therapy
* patients must be willing to discontinue alcohol use for 15 days (maximum duration of treatment plus one day)
* patients must be willing to discontinue use of antacids for duration of study treatment
* patients must not have used proton pump inhibitors (PPI) within 30 days of registration. Patients also must be willing to stop using non-study provided PPIs until the completion of the 6 week follow-up contact.
* patients must not have been treated with antibiotics for H. pylori in the past and must not have taken any other antibiotics within 30 days of registration.
* patients must be willing to return for 2 follow-up visits: 6 weeks after randomization following completion of treatment \& 1 year after randomization
* patients must be willing to allow submission of blood for assays of serum markers of bacterial virulence and host genetic susceptibility and environmental factors and provide consent for use of specimens.

Exclusion Criteria:

* current use of anti-retroviral therapy for HIV or AIDS
* diagnosed congestive hear failure
* renal failure requiring dialysis
* diagnosed hepatic failure resulting in hyperbilirubinemia
* any current or prior malignancy except: adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or Stage II cancer from which the patient has been disease free for 5 years
* pregnancy or nursing mothers

Answer: C